Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Generics Applications Fall, As EMA’s Interim Report Hopes To Herald Funding Renewal

This article was originally published in The Pink Sheet Daily

Executive Summary

European Commission intervention has stopped duplicate generic applications. EMA hopes to end its budget row with the EU Parliament by focusing on transparency and conflict of interest disclosures.

You may also be interested in...



EU SCOPE Project Will Harmonize Pharmacovigilance, Benefit Industry

The EU SCOPE pharmacovigilance project will harmonize practices across the 28 member states, thereby cutting the administrative and cost burden for pharmaceutical manufacturers.

Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root

EMA’s plans for access to clinical trials data not set to be ready until well into 2014.

EMA Director-Nominee Guido Rasi Brings Track Record For Repairing Regulatory Agency Reputation

Rasi leads the Italian Medicines Agency, an agency also known for conditional reimbursement agreements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel